Aurora-A kinase inhibitor scaffolds and binding modes

Drug Discovery Today

Volumn 16, Issue 5-6, 2011, Pages 260-269

  Yan, Aixia ^a   Wang, Liyu ^a   Xu, Shuyu ^a   Xu, Jun ^b  

^a BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,5,6 TETRAHYDROPYRROLO[3,4 C]PYRAZOLE; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; ATP COMPETITIVE INHIBITOR; AURORA A KINASE; AURORA A KINASE INHIBITOR; AURORA B KINASE; AURORA C KINASE; AURORA KINASE INHIBITOR; BARASERTIB; DANUSERTIB; ENZYME INHIBITOR; IMATINIB; IMIDAZOLE; MLN 8237; MOLECULAR SCAFFOLD; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PACLITAXEL; PROTEIN SERINE THREONINE KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE; PYRIMIDINE DERIVATIVE; PYRROLO[2,3 B]PYRIMIDINE; TETRAHYDROPYRROLO[3,4 C]PYRAZOLE; TOZASERTIB; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL PROLIFERATION; CENTROSOME; CHROMOSOME; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLON CANCER; CYTOKINESIS; DIGESTIVE SYSTEM CANCER; DRUG ABSORPTION; DRUG BINDING; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVE SITE; ENZYME INHIBITION; EPITHELIAL OVARY CANCER; GASTROESOPHAGEAL CANCER; GENE EXPRESSION; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; IC 50; NEOPLASM; NEUTROPENIA; NONHUMAN; OVARY CANCER; PERITONEUM CANCER; PHARMACODYNAMICS; PRIMARY PERITONEAL CANCER; PROGNOSIS; PROSTATE CANCER; PROTEIN FOLDING; PROTEIN LOCALIZATION; QT PROLONGATION; REVIEW; RNA INTERFERENCE; SOLID TUMOR; SOMNOLENCE; UTERINE TUBE CARCINOMA;

ANIMALS; BINDING SITES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 79952447362     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.12.003     Document Type: Review

References (50)

1. J.R. Brown, and R.N. DuBois COX-2: a molecular target for colorectal cancer prevention J. Clin. Oncol. 4 2005 2840 2855 (Pubitemid 46179475)
2. T. Sardon Development and biological evaluation of a novel Aurora A kinase inhibitor ChemBioChem 10 2009 464 478
3. J.R. Pollard, and M. Mortimore Discovery and development of Aurora kinase inhibitors as anticancer agents J. Med. Chem. 52 2009 2629 2651
4. J.J.E.M. Kitzen Aurora kinase inhibitors Crit. Rev. Oncol. Hematol. 73 2010 99 110
5. M. Malumbres, and M. Barbacid Cell cycle kinases in cancer Curr. Opin. Genet. Dev. 17 2007 60 65 (Pubitemid 46109297)
6. E.A. Nigg Mitotic kinases as regulators of cell division and its checkpoints Nat. Rev. Mol. Cell Biol. 2 2001 21 32 (Pubitemid 33676958)
7. G. Mountzios Aurora kinases as targets for cancer therapy Cancer Treat. Rev. 34 2008 175 182 (Pubitemid 351372885)
8. R. Giet Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol. 15 2005 241 250 (Pubitemid 40603893)
9. S. Wang Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora kinase inhibitors J. Med. Chem. 53 2010 4367 4378
10. D. Mahadevan, and S. Beeck Aurora kinase targeted therapeutics in oncology: past, present and future Expert Opin. Drug Discov. 2 2007 1011 1026 (Pubitemid 47162386)
11. H. Yang Mitotic requirement for Aurora A kinase is bypassed in the absence of Aurora B kinase FEBS Lett. 579 2005 3385 3391 (Pubitemid 40800286)
12. I. Aliagas-Martin A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B J. Med. Chem. 52 2009 3300 3307
13. W. Lok Aurora kinase inhibitors as anti-cancer therapy Anticancer Drugs 21 2010 339 350
14. X. Li Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-C J. Biol. Chem. 279 2004 47201 47211 (Pubitemid 39518377)
15. K. Sasai Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells Cell Motil. Cytoskeleton 59 2004 249 263 (Pubitemid 40012993)
16. R. Giet, and C. Prigent Aurora/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases J. Cell Sci. 112 1999 3591 3601 (Pubitemid 129783931)
17. R. Crane Requirements for the destruction of human Aurora-A J. Cell Sci. 117 2004 5975 5983 (Pubitemid 40123964)
18. A.O. Walter The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation Oncogene 19 2000 4906 4916
19. R. Bayliss Structural basis of Aurora-A activation by TPX2 at the mitotic spindle Mol. Cell 12 2003 851 862 (Pubitemid 37352779)
20. L.E. Littlepage Identification of phosphorylated residues that affect the activity of the mitotic kinase aurora-A Proc. Natl. Acad. Sci. U. S. A. 99 2002 15440 15445 (Pubitemid 35403953)
21. T.T. Talele, and M.L. McLaughlin Molecular docking/dynamics studies of Aurora A kinase inhibitors J. Mol. Graph. Model. 26 2008 1213 1222
22. D. Fancelli Potent and selective aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition J. Med. Chem. 48 2005 3080 3084 (Pubitemid 40548120)
23. N.M. Heron SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors Bioorg. Med. Chem. Lett. 16 2006 1320 1323 (Pubitemid 43143015)
24. Fancelli, D. et al. (2007) [Nerviano Medical Sciences] Preparation of 1H-thieno[2,3-c]pyrazoles as kinase, particularly Aurora kinases and IGF-1R inhibitors for treating cancer. PIXXD2 WO 2007009898 A1 20070125
25. Barberis, C. et al. (2006) [Aventis Pharma] Hydrazinocarbonyl-thieno[2,3- c]pyrazoles, their preparation, compositions containing them and their use as inhibitors of protein kinases. PIXXD2 WO 2006092510 A1 20060908
26. Carry, J.C. et al. (2006) [Aventis Pharma] Substituted 1H-thieno[2,3-c]pyrazoles, their preparation, compositions containing them and their use as inhibitors of protein kinases for treating cancer. PIXXD2 WO 2006056697 A1 20060601
27. Mauger, J. et al. (2007) [Aventis Pharma] Preparation of 1,4-dihydropyridine-fused heterocycles as inhibitors of Aurora kinases. EPXXDW EP 1746097 A1 20070124
28. K.J. Moriarty The synthesis and SAR of 2-amino-pyrrolo [2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors Bioorg. Med. Chem. Lett. 16 2006 5778 5783 (Pubitemid 44486744)
29. Fischer, P.M. et al. (2006)[Cyclacel Ltd.] Preparation of 4-(1H-indol-3-yl)-pyrimidin-2-ylamine derivatives as protein kinase inhibitors and their use in therapy. PIXXD2 WO 2006075152 A1 20060720
30. Tabart, M. et al. (2006) [Aventis Pharma] Preparation of substituted pyrrolopyridines as kinase inhibitors, and their compositions and use for treatment of cancer. FRXXBL FR 2884821 A1 20061027
31. Georges, G. et al. (2006) [F. Hoffmann-La Roche] Preparation of pyrazolylbenzimidazole derivatives as Aurora A kinase inhibitors for treatment of cancer. PIXXD2 WO 2006032519 A1 20060330
32. Bavetsias, V. et al. (2007) [Chroma Therapeutics Ltd.] Preparation of imidazopyridines as enzyme inhibitors, especially Aurora kinase inhibitors, for treating cell proliferative diseases. PIXXD2 WO 2007072017 A2 20070628
33. Lew, W. et al. (2006) [Sunesis Pharmaceuticals] Thienopyrimidines useful as Aurora kinase inhibitors and their preparation, pharmaceutical compositions, and their use for treatment of Aurora kinase-mediated diseases. USXXCO US 2006035908 A1 20060216
34. Davidson, A.H. et al. (2006) [Chroma Therapeutics Ltd.] Preparation of quinoline and quinazoline amino acid derivatives as inhibitors of kinase enzymatic activity. PIXXD2 WO 2006117552 A1 20061109
35. Tomozane, H. et al. (2005) [Mitsubishi Pharma Corporation] Preparation of aminopyrimidine derivatives as aurora 2 kinase inhibitors for treatment of cancer. PIXXD2 WO 2005113550 A1 20051201
36. Adams, J.L. et al. (2007) [Smithkline Beecham Corporation] Pyrimidinyl-pyrazole inhibitors of Aurora kinases and their preparation, pharmaceutical compositions and use in the treatment of cell proliferative diseases. PIXXD2 WO 2007024843 A2 20070301
37. Jones, S. et al. (2007) [Cyclacel Ltd.] Preparation of pyrimidinyl substituted pyrrolopyrazinones as protein kinase inhibitors useful in treatment of diseases. PIXXD2 WO 2007042784 A2 20070419
38. Krueger, E.B. et al. (2008) [Genentech, Inc.] Preparation of pyrimidines as Aurora kinase inhibitors. PIXXD2 WO 2008079719 A1 20080703
39. S. Howard Fragment-based discovery of the pyrazol-4-yl urea (AT9283). A multitargeted kinase inhibitor with potent Aurora kinase activity J. Med. Chem. 52 2009 379 388
40. M. Zhong 2-Aminobenzimidazoles as potent Aurora kinase inhibitors Bioorg. Med. Chem. Lett. 19 2009 5158 5161
41. C.H.A. Cheung Aurora kinase inhibitors in preclinical and testing Expert Opin. Investig. Drugs 18 2009 379 398
42. D. Fancelli 1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile J. Med. Chem. 49 2006 7247 7251 (Pubitemid 44886012)
43. L.W. Tari Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors Bioorg. Med. Chem. Lett. 17 2007 688 691 (Pubitemid 46127641)
44. B. Zhao Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2 Protein Sci. 17 2008 1791 1797
45. M.G. Manfredi Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase Proc. Natl. Acad. Sci. U. S. A. 104 2007 4106 4111 (Pubitemid 47181586)
46. B.B. Gadea, and J.V. Ruderman Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts Mol. Biol. Cell 16 2005 1305 1318 (Pubitemid 40349566)
47. T. Ikezoe A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia Mol. Cancer Ther. 6 2007 1851 1857 (Pubitemid 46954062)
48. E.A. Harrington VX-680, a potent and selective small molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo Nat. Med. 10 2004 262 267 (Pubitemid 38667616)
49. E. Montembault, and C. Prigent Aurora kinases: therapeutic potential Drug Fut. 30 2005 1 9
50. Jones, S.F. et al. (2007) Phase I clinical trial of MLN8054, a selective inhibitor of Aurora A kinase. J. Clin. Oncol., 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007: 3577. (http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst-detail- view&confID=47&abstractID=34708 )